All In MedTech

Device Trial Radar · NCT07645118

Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer

Pilot Evaluation of the Immunogenic Potentiation of Neo-adjuvant Brachytherapy Followed by Nivolumab Immunotherapy Without Chemotherapy in Stage II/III Locally Advanced Mismatch Repair Proficient Rectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Oct 22, 2026

Primary completion

Dec 2028

Study completion Dec 2030

Sponsor

Lead sponsor
Dr. Te VuongAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 12, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a small Phase II study testing whether targeted internal radiation treatment (HDREBT) followed by two doses of the immunotherapy drug Nivolumab is safe, practical, and potentially effective before patients undergo surgery (TME) to remove rectal cancer.

Conditions

  • Locally Advanced Rectal Cancer

Interventions

  • NivolumabDrug

    2 doses of nivolumab 3 mg/kg mg IV every 2 weeks

  • HDRBETDevice

    26 Gy in 4 fractions Administered over Days 1-4 as per institutional standard

  • Total Mesorectal Excision (TME)Procedure

    Targeted to take place 6-8 weeks post completion of HDREBT (maximum 12 weeks)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathologic complete response (pCR)Time frame: This is assessed at the time of total mesorectal excision surgery, occurring approximately 12 weeks after enrollment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jewish General Hospital

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.